Clinical trials: Hyperkeratosis
Actinic Keratoses
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis…
- Trial name
- NCT03575780
- Testing
- KX2-391 Ointment 1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Athenex, Inc.
Actinic Keratosis
Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.
The aim of the study was to evaluate the efficacy and safety of BF-200 ALA (Ameluz) used with photodynamic therapy (PDT) in patients suffering from actinic keratosis.
- Trial name
- NCT02799082
- Testing
- Vehicle, BF-200 ALA
- Volunteers
- 122 people
- Sponsor
- Biofrontera Bioscience GmbH
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the…
- Trial name
- NCT03285490
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp.
- Trial name
- LEIDA 2 (NCT01453179)
- Testing
- Imiquimod, Diclofenac
- Where
- 17 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Congenital Ichthyosis
A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital ichthyosis (CI) is a large, heterogeneous family of inherited skin disorders of cornification resulting from an abnormality of skin keratinization, such as scaling and thickening of the skin.
- Trial name
- NCT02864082
- Testing
- PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Patagonia Pharmaceuticals, LLC
Field Actinic Keratoses, Basal Cell Carcinoma
Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease
The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic…
- Conditions
- Field Actinic Keratoses, Basal Cell Carcinoma, Bowen's Disease
- Trial name
- NCT00535080
- Testing
- Metvix (methyl aminolevulinate)
- Sponsor
- Galderma R&D
Lesion Skin, Seborrheic Keratosis
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study
Primary study objective is to evaluate the optimization of Nano-Pulse Stimulation (NPS) energy settings for lesion clearance of Seborrheic Keratosis (SKs) from off-facial areas of healthy adults.
- Conditions
- Lesion Skin, Seborrheic Keratosis, Skin Lesion, Benign Skin Tumor
- Trial name
- NCT04249115
- Testing
- Nano-Pulse Stimulation (NPS)
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Pulse Biosciences, Inc.
Actinic Keratosis
Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis
The purpose of this study is to assess the efficacy, safety and tolerability of Eryfotona AK-NMSC® topical application vs Sunscreen on cancerization field of actinic keratosis patients after 6 months of treatment.
- Trial name
- NCT01656226
- Testing
- Eryfotona AK-NMSC® cream, Sunscreen SPF 50+
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- ISDIN